[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bulimia-nervosa\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bulimia-nervosa":31},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,30,0,25,[9,54,80,111,147,169,185,213,236,257,276,362,381,410,436,490,522,546,574,593,618,647,676,700,721],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":34,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100639845","eating-disorder-dynamic-intervention-100639845",false,"NCT07600671","Eating Disorder Dynamic Intervention","Rapid Innovation of Precision Psychiatry Interventions Using Dynamic Systems Modeling and Ecological Quasi-Experiments","EDDI","Inclusion Criteria:\n\n1. Age 18-70\n2. At least 12 ED behaviors from the same behavioral category in the past 12 weeks (i.e., at least 12 binge eating episodes, at least 12 compensatory behaviors, and\u002For at least 12 instances of dietary restriction)\n3. Ownership of a smartphone\n4. Willingness to complete ecological momentary assessment (EMA) and sensor data collection\n5. Live in the United States\n6. Has a primary care provider or is willing to establish a primary care provider\n\nExclusion Criteria:\n\n1. Inability to fluently speak, read, and write in English\n2. Body mass index \\\u003C 17.5 kg\u002Fm2\n3. Medical complications of ED symptoms requiring immediate treatment\n4. Current ED-focused therapy\n5. Severe psychopathology (i.e., active suicidal ideation, psychosis, bipolar disorder, or substance use disorder) or intellectual disability inhibiting engagement in study protocols","ALL","18 Years","70 Years",{"count":22,"type":23},170,"ESTIMATED","INTERVENTIONAL",[26],"NA","The goal of this study is to develop and test a digital program to help people with eating disorders in their everyday lives. The program uses brief surveys and sensor data collected by smartphones to understand when someone may be at higher risk for behaviors like restricting food, binge eating, or using unhealthy weight control behaviors.",[29,30,31,32,33],"Eating Disorders","Anorexia Nervosa","Bulimia Nervosa","Binge Eating Disorder","Other Specified Feeding or Eating Disorder",[35,36,37,38,39,40,41],"binge eating","eating problem","eating disorder","purging","restriction","weight control behavior","dieting","RECRUITING","2026-06-29",{"date":45,"type":46},"2026-07-01","ACTUAL",{"date":43,"type":46},{"date":49,"type":23},"2030-07-31",{"name":51,"class":52},"Trustees of Dartmouth College","OTHER",1,{"id":55,"slug":56,"hasResults":12,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":24,"phases":63,"briefSummary":65,"conditions":66,"keywords":67,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":53},"100634627","phase-1-mdma-assisted-therapy-for-bn-100634627","NCT07542145","MDMA Assisted Therapy for BN","MDMA Assisted Therapy for Bulimia Nervosa: A Treatment Development Protocol","Inclusion Criteria:\n\nParticipants will be included in the protocol if they meet the following criteria:\n\n* At least 18 years of age\n* Meet criteria for Bulimia Nervosa as measured by the EDA-5\n* Able to provide written, informed consent\n* Able to swallow pills\n* Agree to have study visits recorded, including Experimental Sessions and non-medication therapy sessions\n* Provides a contact (relative, spouse, close friend or other support person) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal or unreachable\n* Agrees to inform the investigators within 48 hours of any medical conditions and procedures\n* If able to become pregnant, must have a negative pregnancy test at study entry and prior to each Experimental Session, and must agree to use adequate contraceptive methods through 10 days after the last Experimental Session. Adequate contraceptive methods include intrauterine device (IUD), injected, implanted, intravaginal, or transdermal hormonal methods, abstinence, oral hormones plus a barrier contraception, vasectomized sole partner, or double barrier contraception. Two forms of contraception are required with any barrier method or oral hormones (i.e., condom plus diaphragm, condom or diaphragm plus spermicide, oral hormonal contraceptives plus spermicide or condom). 'Not able to become pregnant' is defined as permanent sterilization, postmenopausal, or assigned male at birth\n* Agrees to the lifestyle modifications\n* Live within reasonable driving distance of the study site (equal to or less than an estimated 2-hour drive from the study site).\n* Have an identified Primary Care Physician (PCP) and provide consent for the investigator to communicate with PCP, as needed.\n* Current or past treatment were not successful to retain remission (i.e., continued to meet criteria for BN) despite participating in at least one ED-specific episode of treatment (inpatient, residential, partial hospitalization, intensive outpatient), as confirmed by medical records, by a general practitioner, or by a specialist in ED.\n* Are medically stable according to screening 12-lead Electrocardiogram (ECG), blood pressure monitoring, blood and urine laboratory screening results, and medical history.\n\nExclusion Criteria:\n\nParticipants will be excluded from participation for the following reasons:\n\n* Alanine transaminase (ALT) \\[or aspartate transaminase (AST)\\] \\> 2 x upper limit of normal (ULN). Total bilirubin \\> 1.5 x ULN (isolated bilirubin \\> 1.5 x ULN is acceptable if total bilirubin is fractionated and direct bilirubin \\\u003C 35%).\n* Estimated glomerular filtration rate (eGFR) less than 60.\n* Current unstable liver or biliary disease per investigator assessment defined by presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. Note: Stable chronic liver disease (including Gilbert's syndrome, asymptomatic gallstones, and chronic stable hepatitis B (e.g., the presence of hepatitis B surface antigen or positive hepatitis C antibody test result without evidence of active infection at screening or within 3 months prior to starting study intervention) is acceptable if the participant otherwise meets entry criteria.\n* Self-induced vomiting of over 14 times per week\n* Symptomatic Hepatitis C virus (HCV)\n* Moderate alcohol or cannabis use disorder (meets \\> 3 of 11 diagnostic criteria per DSM-5) or moderate alcohol or cannabis use disorder in early remission for the 3 months prior to enrollment (meets 4 or 5 of 11 diagnostic criteria per DSM-5)\n* Diabetes Type 1 or Unstable Type 2 Diabetes\n* Untreated hypothyroidism\n* Are likely, in the investigator's opinion and via observation during the Preparatory Period, to lack social support or a stable living situation\n* Have used Ecstasy (material represented as containing MDMA) more than 10 times within the last 10 years or at least once within 6 months of the first Experimental Session;\n* Have previously participated in a MAPS-sponsored MDMA clinical trial\n* Have any current problem which, in the opinion of the investigator or study clinician, might interfere with participation\n* Have hypersensitivity to any ingredient of the IMP (Investigational Medicinal Product)\n* Have received Electroconvulsive Therapy (ECT) within 12 weeks of enrollment\n* Have a history of or a current primary psychotic disorder, bipolar disorder 1 assessed via CAT-MH and confirmed via clinical interview or dissociative identity disorder assessed via DDIS and confirmed via clinical interview\n* Have current major depressive disorder with psychotic features assessed via CAT-MH\n* Have a current moderate (not in early remission in the 3 months prior to enrollment; meets 4 or 5 of 11 diagnostic criteria per DSM-5) or severe alcohol or cannabis use disorder within the 12 months prior to enrollment (meets at least 6 of 11 diagnostic criteria per DSM-5)\n* Have an active illicit drug or prescription drug substance use disorder at any severity (other than cannabis) within 12 months prior to enrollment\n* Any participant presenting current serious suicide risk, as determined through psychiatric interview, responses to C-SSRS, and clinical judgment of the investigator will be excluded; however, history of suicide attempts is not an exclusion. Any participant who is likely to require hospitalization related to suicidal ideation and behavior, in the judgment of the investigator, will not be enrolled. Any participant presenting with the following on the Baseline C-SSRS will be excluded: a. Suicidal ideation score of 4 or greater within the last month of the assessment at a frequency of once a week or more; b. Suicidal ideation score of 5 within the last 6 months of the assessment; c. Any suicidal behavior, including suicide attempts or preparatory acts, within the last 6 months of the assessment. Participants with non-suicidal self-injurious behavior may be included if approved by the study clinician\n* Would present a serious risk to others as established through clinical interview and contact with treating psychiatrist\n* Require ongoing concomitant therapy with a psychiatric medication with exceptions described the Concomitant Medications Section\n* Have a history of any medical condition that could make receiving a sympathomimetic drug harmful because of increases in blood pressure and heart rate. This includes, but is not limited to, a history of myocardial infarction, cerebrovascular accident, or aneurysm. Participants with other mild, stable chronic medical problems may be enrolled if the study physician and Sponsor-investigator agree the condition would not significantly increase the risk of MDMA administration or be likely to produce significant symptoms during the study that could interfere with study participation or be confused with side effects of the IMP. Examples of stable medical conditions that could be allowed include, but are not limited to Diabetes Mellitus (Type 2), Human Immunodeficiency Virus (HIV) infection, Gastroesophageal Reflux Disease (GERD), etc. Any medical disorder judged by the investigator to significantly increase the risk of MDMA administration by any mechanism would require exclusión\n* ASCVD Risk Estimator 10-year cardiovascular risk of 7.5% or higher\n* Duke Activity Status Index (DASI) METs score less than 4\n* Have a diagnosis of uncontrolled essential hypertension which is assessed using the recommended criteria of the American Heart Association for Stage 2 hypertension (values of 140\u002F90 milligrams of Mercury \\[mmHg\\] or higher assessed on three separate occasions)\n* Have a history of ventricular arrhythmia at any time, other than occasional premature ventricular contractions (PVCs) in the absence of ischemic heart disease\n* Have Wolff-Parkinson-White syndrome or any other accessory pathway that has not been successfully eliminated by ablation\n* Have a history of supraventricular arrhythmia within the last 12 months. Participants with a history of an allowable supraventricular arrhythmia (see list below) more than 12 months prior to screening and in the absence of any accessory pathway may be enrolled if successfully treated at least 12 months prior and cleared by a cardiologist, and the study clinician. These arrhythmias may include, and must be limited to, paroxysmal supraventricular tachycardia, paroxysmal atrial tachycardia, or atrial fibrillation that has been successfully treated (e.g., with ablation or cardioversion) at least 12 months previously. Atrial flutter or other arrhythmias will be excluded\n* Have a marked baseline prolongation of QT\u002FQTc interval (e.g., repeated demonstration of a QTcF interval \\>450 milliseconds \\[ms\\]\n* Have a history of additional risk factors for Torsade de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)\n* Require use of concomitant medications that prolong the QT\u002FQTc interval during Experimental Sessions. Refer to Concomitant Medications Section\n* Have history of hyponatremia or hyperthermia\n* Weigh less than 48 kilograms (kg)\n* Are pregnant or nursing or are able to become pregnant and are not practicing an effective means of contraception\n* Have a blood or needle phobia that interferes with obtaining necessary blood work.\n* Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the sponsor-investigator or study clinician, contraindicates participation in the study.\n* Expressed that they are not comfortable in participating in therapy and conducting assessments in English.\n* Blood disorder or infection indicated by CBC assay that would be contraindicated for MDMA.\n* Thyroid condition (hyperthyroidism) indicated by TSH that would prevent body temperature regulation and be contraindicated for MDMA\n* Urinalysis results indicating electrolytes\u002Fkidney disfunction",{"count":62,"type":23},40,[64],"PHASE1","This project will evaluate MDMA Assisted Therapy (MDMA-AT) assisted psychotherapy for the treatment of Bulimia Nervosa (BN) over a 10-week period. Preliminary data suggests that MDMA can facilitate heightened openness and reduce anxiety. This study will determine whether MDMA-assisted therapy can serve as a new treatment for BN. Participants are assigned to one of three groups: MDMA-AT, MDMA-AT-BN, and Standard Treatment (ST). MDMA groups include three experimental session that include dosing, which are each followed by three integrative sessions and also include 12 psychotherapy sessions. A follow-up will take place at 6-months post baseline.",[31],[31,68,29,69,70],"MDMA-assisted therapy","Binge Eating","BN","2026-06-17",{"date":73,"type":46},"2026-06-22",{"date":75,"type":46},"2026-05-22",{"date":77,"type":23},"2028-04-30",{"name":79,"class":52},"Icahn School of Medicine at Mount Sinai",{"id":81,"slug":82,"hasResults":12,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":12,"sex":87,"minAge":19,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":24,"phases":90,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":53},"100639374","understanding-and-targeting-self-regulatory-control-in-bulimia-nervosa-100639374","NCT07581158","Understanding and Targeting Self-Regulatory Control in Bulimia Nervosa","Understanding and Targeting Self-Regulatory Control in Bulimia Nervosa Via a Combined Real-Time Neurofeedback and Smartphone Intervention","Inclusion criteria:\n\n* Female\n* Aged 18 to 55 years\n* Meet diagnostic criteria for bulimia nervosa (BN) or BN of low frequency and\u002For limited duration\n* Current body mass index greater than or equal to 18.5kg\u002Fm2 but under 40kg\u002Fm2\n* English-speaking\n\nExclusion criteria:\n\n* Ongoing medical treatment or planned\u002Frecent change in medical treatment, major medical condition, or psychiatric disorder that may interfere with study variables or participation\n* Current psychotherapy focused primarily on eating disorder symptoms\n* Pregnancy or planned pregnancy, or lactation during the study period\n* Allergy to ingredients in the shake","FEMALE","55 Years",{"count":62,"type":23},[26],"The purpose of this study is to examine the effects of noninvasive prefrontal cortex (PFC) neurofeedback during eating in women with bulimia nervosa (BN) using wearable brain imaging, functional near-infrared spectroscopy (fNIRS), together with a brain-based 4-week text-messaging intervention. The investigators will examine how these interventions may influence inhibitory control and eating disorder symptoms in women with bulimia nervosa.",[31,93,94],"Feeding and Eating Disorders","Mental Disorders",[96,97,98,99,100,101],"fNIRS","fNIRS neurofeedback","smartphone intervention","eating disorders","bulimia nervosa","bulimia","NOT_YET_RECRUITING","2026-05-06",{"date":105,"type":46},"2026-05-12",{"date":107,"type":23},"2026-04-25",{"date":109,"type":23},"2028-12-14",{"name":79,"class":52},{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":24,"phases":122,"briefSummary":123,"conditions":124,"keywords":129,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":53},"100531301","targeting-social-function-in-anxiety-and-eating-disorders-100531301","NCT06198023","Targeting Social Function in Anxiety and Eating Disorders","Targeting Social Function to Improve Outcomes in Anxiety and Eating Disorders","SF","Inclusion Criteria:\n\n* In the past 12 months, has met DSM-5 criteria met for an eating disorder (Anorexia Nervosa, Atypical Anorexia Nervosa, Bulimia Nervosa, Avoidant-Restrictive Food Intake Disorder, or Other Specified Feeding or Eating Disorder) and\u002For an anxiety disorder (Generalized Anxiety Disorder, Social Anxiety Disorder)\n* Between the ages of 18-30\n\nExclusion Criteria:\n\n* Current inpatient or residential treatment\n* Medical instability or safety\u002Fsuicide risk as determined by the PI","30 Years",{"count":121,"type":23},60,[26],"Social processing and cognition are often altered in patients with eating disorders. The goal of this clinical trial is to assess two different social therapeutic interventions -- one educational, one interactive -- for their effectiveness in improving clinical outcomes in patients with eating disorders. Patients in both interventions will receive education about social function in eating disorders, but those in the interactive treatment group will complete an additional collaborative art task.\n\nParticipants will:\n\n* attend a baseline study visit to complete clinical interviews, cognitive testing, and behavioral tasks\n* complete a pre-intervention assessment with questionnaires\n* attend eight sessions of their assigned treatment group over the course of 12 weeks\n* complete three virtual follow-up assessments 4, 8, and 12 months from their baseline\n* attend a final study visit to repeat some clinical interviews, cognitive testing, and behavioral tasks\n\nResearchers will compare changes in eating disorder, mood, and anxiety symptoms as well as test results from baseline and final study visits for each group to see if\n\n* patients can be treated effectively with education alone or if an interactive group component produces additional benefits\n* cognitive and behavioral task performance are associated with recovery or illness state.",[29,30,31,125,126,33,127,128],"Atypical Anorexia Nervosa","Purging (Eating Disorders)","Social Anxiety Disorder","Generalized Anxiety Disorder (GAD)",[130,131,132,133,134,135,136,137],"social function","social cognition","social processing","psychoeducation","group therapy","group intervention","art therapy","social anxiety","2026-04-28",{"date":140,"type":46},"2026-05-05",{"date":142,"type":46},"2024-02-28",{"date":144,"type":23},"2028-09",{"name":146,"class":52},"University of Texas Southwestern Medical Center",{"id":148,"slug":149,"hasResults":12,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":153,"sex":87,"minAge":19,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":157,"phases":4,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":53},"100559629","avoidance-driven-decision-making-and-learning-in-anorexia-nervosa-and-bulimia-nervosa-100559629","NCT06566612","Avoidance-driven Decision Making and Learning in Anorexia Nervosa and Bulimia Nervosa","Inclusion Criteria:\n\nEating Disorder Group:\n\n* Between the ages of 18 and 39 years old\n* Meet DSM-V criteria for anorexia nervosa or bulimia nervosa\n\nHealthy Controls:\n\n* Between the ages of 18 and 39 years old\n* Have maintained 85% to 120% ideal body weight since menarche\n\nExclusion Criteria:\n\n* Psychotic illness\u002Fother mental illness requiring hospitalization\n* Current dependence on drugs or alcohol defined by DSM IV criteria. Additionally, positive test results for drug use on the day of the scan, apart of marijuana, will result in cancelling or rescheduling the scan because acute use will impact MRI measures.\n* Physical conditions (e.g. diabetes mellitus, pregnancy) known to influence eating or weight\n* Neurological disorder, neurodevelopmental disorder, or history of head injury with \\>30 min loss of consciousness\n* Any contraindication to undergoing an MRI\n* Primary obsessive compulsive disorder or primary major depressive disorder\n\nAdditional Exclusion Criteria for ED Group:\n\n* If taking other psychotropic medication, any change in dosage in the 2 weeks before scanning\n\nAdditional Exclusion Criteria for Healthy Control Group:\n\n* Meet criteria for the diagnosis of any psychiatric disorder currently\n* Any history of binge eating or purging behaviors, including self-induced vomiting, laxative or diuretic misuse\n* Use of any psychoactive or other medication known to affect mood or concentration in the last 3 months",true,"39 Years",{"count":156,"type":23},78,"OBSERVATIONAL","The purpose of this study is to investigate areas of the brain responsible for avoidance learning in adults with eating disorders using brain imaging techniques, computer tasks, and self-report questionnaires and interviews. The investigators will study changes in brain activity using a procedure called functional magnetic resonance imaging (fMRI). This study will include 78 women with an eating disorder (26 with anorexia nervosa \\[AN\\], 26 with bulimia nervosa \\[BN\\]) and 26 healthy controls (HC) aged 18-39.\n\nAim 1: Evaluate behavioral differences in active and passive avoidance learning in eating disorders and associations with symptoms.\n\nAim 2: Evaluate whether corticostriatal and limbic-prefrontal fMRI BOLD response associated with avoidance learning differs in eating disorders relative to healthy controls and relates to symptoms.\n\nAim 3: Evaluate whether functional connectivity of avoidance learning neural circuity differs in eating disorders relative to healthy controls.",[31,30],"2026-04-27",{"date":162,"type":46},"2026-05-01",{"date":164,"type":46},"2024-08-01",{"date":166,"type":23},"2027-07-31",{"name":168,"class":52},"University of California, San Diego",{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":153,"sex":87,"minAge":19,"maxAge":154,"enrollmentInfo":175,"targetDuration":4,"studyType":157,"phases":4,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":179,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":53},"100443606","incentive-processing-and-learning-in-anorexia-nervosa-and-bulimia-nervosa-100443606","NCT05056597","Incentive Processing and Learning in Anorexia Nervosa and Bulimia Nervosa","Inclusion Criteria:\n\nEating Disorder Group:\n\n* Between the ages of 18 and 39 years old\n* Meet DSM-V criteria for AN-R, AN-BP, or BN\n\nHealthy Control Group:\n\n* Between the ages of 18 and 39 years old\n* Have maintained 85% to 120% ideal body weight since menarche\n\nExclusion Criteria:\n\nAll Groups:\n\n* Psychotic illness\u002Fother mental illness requiring hospitalization\n* Current dependence on drugs or alcohol defined by DSM IV criteria. Additionally, positive test results for drug use on the day of the scan, apart of marijuana, will result in cancelling or rescheduling the scan because acute use will impact MRI measures.\n* Physical conditions (e.g. diabetes mellitus, pregnancy) known to influence eating or weight\n* Neurological disorder, neurodevelopmental disorder, or history of head injury with \\>30 min loss of consciousness\n* Any contraindication to undergoing an MRI\n* Primary obsessive compulsive disorder or primary major depressive disorder\n\nAdditional Exclusion Criteria for ED Group:\n\n-If taking other psychotropic medication, any change in dosage in the 2 weeks before scanning\n\nAdditional Exclusion Criteria for Healthy Control Group:\n\n* Meet criteria for the diagnosis of any psychiatric disorder currently\n* Any history of binge eating or purging behaviors, including self-induced vomiting, laxative or diuretic misuse\n* Use of any psychoactive or other medication known to affect mood or concentration in the last 3 months",{"count":176,"type":23},252,"The purpose of this study is to investigate areas of the brain responsible for 'liking', 'wanting', and learning in adults with eating disorders using brain imaging techniques, computer tasks, a test meal, and self-report questionnaires and interviews. The investigators will study changes in brain activity using a procedure called functional magnetic resonance imaging (fMRI). This study will include 252 women with an eating disorder (63 AN-restricting type (AN-R), 63 AN-binge eating\u002Fpurging type (AN-BP), 63 bulimia nervosa (BN)) and 63 healthy controls (HC) aged 18-39.\n\nAim 1: To examine neural differences in 'liking' and 'wanting' in ED relative to HC.\n\nAim 2: To examine differences in instrumental learning for reward and punishment in ED relative to HC.\n\nAim 3: To examine how 'liking' and 'wanting' drive instrumental learning in ED and predict clinical symptoms at baseline and 1 year later.\n\nExploratory Aim: To explore the associations of dopamine function, as measured by neuromelanin MRI (NM-MRI), with ED diagnosis and brain response to 'liking', 'wanting', and learning.",[30,31],{"date":138,"type":46},{"date":181,"type":46},"2022-05-26",{"date":183,"type":23},"2027-01",{"name":168,"class":52},{"id":186,"slug":187,"hasResults":12,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":153,"sex":18,"minAge":193,"maxAge":194,"enrollmentInfo":195,"targetDuration":4,"studyType":157,"phases":4,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":212},"100629733","cognitive-evaluation-of-patients-with-eating-disorders-100629733","NCT07478510","Cognitive Evaluation of Patients With Eating Disorders","Neuro-cognitive Profiles of Patients With Nutritional and Eating Disorders","DNA_ARFID","Inclusion Criteria:\n\n* Diagnosis of a Feeding and Eating Disorder (ARFID, anorexia nervosa, or bulimia nervosa);\n* Patients of both sexes;\n* Age between 14 and 65 years;\n* Confirmed diagnosis of a Feeding and Eating Disorder;\n* Body Mass Index (BMI) \\\u003C 25;\n* Signed informed consent form for participation in the study.\n\nExclusion Criteria:\n\n* Diagnosis of Bipolar Disorder according to DSM-5-TR criteria;\n* Diagnosis of a Schizophrenia Spectrum Disorder according to DSM-5-TR criteria;\n* Intellectual disability according to DSM-5-TR criteria;\n* Presence of brain tumors;\n* History of seizure events;\n* Presence of other moderate to severe neurological disorders;\n* Lack of the patient's consent to voluntary participation in the study;\n* Lack of parental or legal guardian consent for participation of a minor in the study.","14 Years","65 Years",{"count":196,"type":23},84,"The goal of this cross - sectional observational study is to improve understanding of the psychological and cognitive characteristics of Feeding and Eating Disorders (FEDs), a group of conditions that represent a growing public health concern due to their significant impact on physical health, emotional well-being, and everyday functioning. Within this broader diagnostic category, particular attention is given to Avoidant\u002FRestrictive Food Intake Disorder (ARFID), a diagnosis introduced in the DSM-5 and still relatively underexplored compared to other feeding and eating disorders.\n\nDespite its clinical relevance, ARFID remains less well understood in terms of its underlying cognitive and psychological mechanisms. Individuals with ARFID often experience severe food avoidance or restriction that is not driven by weight or shape concerns, but rather by sensory sensitivities, fear of negative consequences of eating, or a lack of interest in food. For this reason, investigating ARFID can offer important insights into the diversity of mechanisms involved in feeding and eating disorders as a whole.\n\nThe study has two main objectives. The first objective is to examine the cognitive profile of individuals with ARFID, with a specific focus on autistic traits and cognitive flexibility, as previous research suggests potential overlaps between ARFID and neurodevelopmental conditions such as Autism Spectrum Disorders. Cognitive flexibility refers to the ability to adapt thoughts and behaviors in response to changing situations, and reduced flexibility may contribute to rigid eating patterns and food avoidance.\n\nThe second objective is to explore the role of body representation (how individuals perceive and mentally represent their own body) and inhibitory control (the ability to regulate or suppress automatic responses) in shaping the cognitive and behavioral features of ARFID and other feeding and eating disorders. These processes may help distinguish ARFID from other diagnoses and clarify shared and disorder-specific mechanisms across the FED spectrum.\n\nThe study involves adult participants of all genders, including individuals diagnosed with ARFID, anorexia nervosa, and bulimia nervosa, as well as healthy control participants without a history of feeding or eating disorders. This design allows meaningful comparisons between different diagnostic groups and with the general population.\n\nThe main questions the study aims to answer are:\n\nDo individuals with ARFID show a distinct cognitive profile, particularly in terms of autistic traits and cognitive flexibility, compared to individuals with other feeding and eating disorders and healthy controls?\n\nHow do body representation and inhibitory control contribute to differences in eating-related behaviors across feeding and eating disorders?\n\nAre there differences in brain activity associated with implicit, automatic attitudes toward food in individuals with feeding and eating disorders compared to healthy individuals?\n\nWhere comparison groups are included, researchers will compare participants with ARFID, anorexia nervosa, bulimia nervosa, and healthy controls to examine differences in cognitive functioning, psychological characteristics, and neural responses related to food processing.\n\nParticipants will be asked to take part in a series of non-invasive and well-established research activities, designed to be accessible and safe. These include:\n\nCompleting self-report questionnaires assessing autistic traits, body image perception, and general psychological well-being;\n\nPerforming computer-based tasks that assess cognitive flexibility and decision-making;\n\nCompleting behavioral tasks designed to measure inhibitory control and automatic associations with food-related stimuli;",[199,30,31,200,201,202],"ARFID","Cognitive Flexibility","Implicit Association Test","Executive Functions","2026-04-15",{"date":205,"type":46},"2026-04-16",{"date":207,"type":46},"2024-11-26",{"date":209,"type":23},"2028-03-31",{"name":211,"class":52},"Istituti Clinici Scientifici Maugeri SpA",3,{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":12,"sex":18,"minAge":220,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":24,"phases":224,"briefSummary":225,"conditions":226,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":53},"100611209","developing-an-artificial-intelligence-ai-chatbot-for-adolescents-and-young-adults-with-eating-disorders-100611209","NCT07237607","Developing an Artificial Intelligence (AI) Chatbot for Adolescents and Young Adults With Eating Disorders","Developing an Artificial Intelligence (AI)-Powered Exposure Therapy Chatbot for Adolescents and Young Adults With Eating Disorders","Inclusion Criteria:\n\n* Age is between or equal to 12-26 years\n* Admitted to the Penn State Health Eating Disorder Partial Hospital Program (PHP) or Intensive Outpatient Program (IOP)\n* Have a personal smartphone\n* Have a diagnosis of anorexia nervosa (AN), bulimia nervosa (BN), binge-eating disorder (BED), or other specified feeding or eating disorder (OSFED)\n* Be English speaking\n\nExclusion Criteria:\n\n* Diagnosis of avoidant\u002Frestrictive food intake disorder (ARFID)\n* Have acute suicidality\n* Diagnosis of an intellectual disability","12 Years","26 Years",{"count":223,"type":23},20,[26],"The goal of this study is to develop and refine an artificial intelligence (AI)-powered Exposure Therapy for Eating Disorders chatbot web-app that effectively engages adolescents and young adults and decreases anxiety about weight gain. Participants will use the web-app as a supplemental therapeutic tool during their first six weeks of treatment in a Partial Hospitalization Program. Participants will complete assessments every two weeks, including: (1) semi-structured interviews about their experience with the chatbot web-app; (2) implementation outcome measures (e.g., feasibility, usability, acceptability); and (3) anxiety about weight gain.",[29,30,31,227],"Binge-Eating Disorder","2026-04-14",{"date":203,"type":46},{"date":231,"type":46},"2026-03-23",{"date":233,"type":23},"2027-06-30",{"name":235,"class":52},"Milton S. Hershey Medical Center",{"id":237,"slug":238,"hasResults":12,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":153,"sex":87,"minAge":19,"maxAge":243,"enrollmentInfo":244,"targetDuration":4,"studyType":24,"phases":246,"briefSummary":247,"conditions":248,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":53},"100515745","changes-in-inhibition-and-valuation-after-eating-100515745","NCT05995496","Changes in Inhibition and Valuation After Eating","Dynamic Neural Computations Underlying Cognitive Control in Bulimia Nervosa","Inclusion Criteria:\n\n* Female\n* Aged 18 to 45 years\n* Current BMI greater than or equal to 18.5kg\u002Fm2 but under 30kg\u002Fm2\n* Right-handed\n* English-speaking\n\nAdditional Inclusion Criteria for Women with Bulimia Nervosa:\n\n* Meet DSM-5 criteria for bulimia nervosa\n\nExclusion Criteria:\n\n* Medical instability\n* Ongoing medical treatment, medical condition, or psychiatric disorder that may interfere with study variables or participation\n* Shift work\n* Pregnancy, planned pregnancy, or lactation during the study period\n* Allergy to any of the ingredients in or unwillingness to consume the standardized meal or unwillingness to drink water during the fasting period\n* Any contraindication for fMRI","45 Years",{"count":245,"type":23},150,[26],"An impaired ability to exert control has been implicated in bulimia nervosa (BN), but this impairment may not represent a stable trait or be the most effective focus for treatment. This project aims to understand how predictions and value-based decisions about control may be abnormally influenced by eating in individuals with BN, thereby maintaining cycles of binge eating, purging, and restriction.",[31],"2026-02-13",{"date":251,"type":46},"2026-02-17",{"date":253,"type":46},"2023-12-12",{"date":255,"type":23},"2027-12-31",{"name":79,"class":52},{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":12,"sex":87,"minAge":19,"maxAge":243,"enrollmentInfo":264,"targetDuration":4,"studyType":24,"phases":265,"briefSummary":266,"conditions":267,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":53},"100486434","neurofeedback-during-eating-for-bulimia-nervosa-100486434","NCT05614024","Neurofeedback During Eating for Bulimia Nervosa","Neurofeedback During Eating: A Novel Mechanistic Treatment for Bulimia Nervosa","Inclusion criteria:\n\n* Female\n* Aged 18 to 45 years\n* Meet diagnostic criteria for bulimia nervosa\n* Current body mass index greater than or equal to 18.5kg\u002Fm2 but under 30kg\u002Fm2\n* English-speaking\n\nExclusion criteria:\n\n* Ongoing medical treatment, major medical condition, or psychiatric disorder that may interfere with study variables or participation\n* Current psychotherapy focused primarily on eating disorder symptoms\n* Pregnancy or planned pregnancy, or lactation during the study period\n* Allergy to ingredients in the standardized meal or in the shake",{"count":5,"type":23},[26],"The purpose of this study is to examine the effects of noninvasive prefrontal cortex (PFC) neurofeedback during eating in women with bulimia nervosa (BN) using a wearable brain imaging device, functional near-infrared spectroscopy (fNIRS). The investigators will examine how this training may influence inhibitory control and BN symptoms.",[31],"2026-01-28",{"date":270,"type":46},"2026-01-30",{"date":272,"type":46},"2024-05-13",{"date":274,"type":23},"2027-12",{"name":79,"class":52},{"id":277,"slug":278,"hasResults":12,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":153,"sex":18,"minAge":283,"maxAge":4,"enrollmentInfo":284,"targetDuration":286,"studyType":157,"phases":4,"briefSummary":287,"conditions":288,"keywords":330,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":53},"100424417","unhide-project-a-digital-health-platform-to-collect-lifestyle-data-for-brain-inflammation-research-100424417","NCT04806620","Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","Unhide® Project Also Known as The Unhide® Solve Together Unified Platform","Participants may be either self-diagnosed, or diagnosed by a physician with the following conditions:\n\n* Infection-associated chronic conditions such as Long COVID, chronic Lyme, myalgic encephalomyelitis (ME\u002FCFS), and post-acute neuropsychiatric syndrome (PANS\u002FPANDAS).\n* Neuroimmune, developmental, autonomic, and neurological conditions like migraines, dysautonomia, POTS, multiple sclerosis, and autism spectrum disorder.\n* Autoimmune diseases such as Lupus, Sjogren's Disease, rheumatoid arthritis, myasthenia gravis, ankylosing spondylitis, and related autoimmune conditions.\n\nInflammatory gastrointestinal conditions such as Crohn's Disease, Celiac Disease, and ulcerative colitis.\n\n* Behavioral and mood disorders such as anxiety, depression, bipolar disorder, PTSD, eating disorders, OCD, and other related conditions.\n* \"Healthy\" people (without brain inflammation), including unaffected individuals, unaffected individuals in the same household, and unaffected individuals who are married to relatives and family members.\n* Have consistent internet access and a cell phone, tablet, or PC since this is an online or app-based platform that requires entering data and completing surveys.\n* Currently live in the United States\n* Be able to participate in English (stay tuned for updates about the Spanish language version)\n* Be willing to share symptom and health data through the platform","2 Years",{"count":285,"type":23},10000,"10 Years","The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from individuals with brain inflammation and related neuroinflammatory conditions. Participants in the United States aged 2 years and older will provide self-reported health data, biometrics, and symptom diaries through the MyDataHelps™ app (branded as unhide® for this study). The goal is to create comprehensive longitudinal profiles to facilitate research into disease subtypes, causes, diagnostics, and potential treatments, as well as to identify potential participants for future optional studies. \"Healthy\" individuals without brain inflammation are also eligible to participate.\n\nThe digital health research platform used in this study was originally developed and designed by Solve M.E and was called SolveTogether. The Brain Inflammation Collaborative (BIC) expanded upon Solve M.E.'s work to include related diagnoses, pediatric participants, enhance symptom tracking, and more. BIC and Solve M.E. combined Solve Together and unhide®, to create The unhide® Solve Together Unified Platform in 2025.",[289,290,291,292,293,294,295,296,297,298,299,300,301,30,31,199,302,303,304,305,306,307,308,309,310,311,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327,328,329],"Post-Acute COVID-19 Syndrome","ME\u002FCFS","Rheumatic Arthritis","Juvenile Rheumatoid Arthritis (JRA)","Psoriatic Arthritis (PsA)","Ankylosing Spondylitis (AS)","Autoimmune Encephalitis","Celiac Disease","Celiac Disease in Children","Chronic Lyme Disease","Post-treatment Lyme Disease Syndrome","Crohn's Disease","Dysautonomia","Avoidant \u002F Restrictive Food Intake Disorder","Ehlers Danlos Syndrome","Endometriosis","Fibromyalgia (FM)","Long COVID","Lupus","Migraines","Mast Cell Activation Syndrome","Multiple Sclerosis","Myalgic Encephalomyelitis (ME)","Myasthenia Gravis, Generalized","Myasthenia Gravis in Children","Narcolepsy","Obsessive Compulsive Disorder (OCD)","PANDAS","Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)","POTS - Postural Orthostatic Tachycardia Syndrome","General Anxiety Disorder, Social Anxiety Disorder","PTSD - Post Traumatic Stress Disorder","Psoriasis","Traumatic Brain Injury","Tourette's Syndrome","Inflammatory Bowel Disease (IBD)","Autoimmune Diseases","Neurological Diseases or Conditions","Psychiatric Disorder","Sjogren's Syndrome","Ulcerative Colitis and Crohn's Disease",[306,331,332,333,334,335,336,337,338,339,290,340,341,342,343,344,308,345,346,347,348,349,350,351,352],"Myalgic Encephalomyelitis","Chronic Fatigue Syndrome","Longitudinal Natural History Study","Observational","Neuroinflammatory Disease","Brain inflammation","Neuroinflammatory disorders","PANS\u002FPANDAS","Autoimmune encephalitis","Dysautonomia \u002F POTS","Multiple sclerosis","Autoimmune disease","Inflammatory bowel disease (Crohn's, ulcerative colitis)","Celiac disease","Mood disorders (anxiety, depression, bipolar, PTSD, OCD)","Mobile health app","Patient registry","Wearable devices","Fatigue","Post-exertional malaise","Brain Fog","Mental health","2026-01-20",{"date":355,"type":46},"2026-01-22",{"date":357,"type":46},"2023-07-05",{"date":359,"type":23},"2030-12-31",{"name":361,"class":52},"Brain Inflammation Collaborative",{"id":363,"slug":364,"hasResults":12,"nctId":365,"briefTitle":366,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":153,"sex":18,"minAge":19,"maxAge":88,"enrollmentInfo":368,"targetDuration":4,"studyType":157,"phases":4,"briefSummary":370,"conditions":371,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":53},"100432896","neurobiological-and-psychological-maintenance-mechanisms-associated-with-anticipatory-reward-in-bulimia-nervosa-100432896","NCT04917068","Neurobiological and Psychological Maintenance Mechanisms Associated With Anticipatory Reward in Bulimia Nervosa","Inclusion Criteria:\n\nBulimia nervosa (BN) and healthy control (HC) groups:\n\n* Right-handed\n* Ability to read and speak in English\n\nBN group only:\n\n* Eating Disorder Examination (EDE) diagnosis of BN (i.e., at least one objective bulimic episode and one self-induced vomiting episode per week for at three months) with binge episodes always accompanied by self-induced vomiting\n* Stable dose for at least 6 weeks of any recent changes in medication impacting mood, appetite, or weight\n\nHC group only:\n\n* No binge eating or purging episodes for the past three months on the EDE\n* No current or past history of an eating disorder as diagnosed by Structured Clinical Interview for DSM-5 Disorders\n\nExclusion Criteria:\n\n* History of gastric bypass surgery\n* Medical condition acutely affecting eating behavior and\u002For weight (i.e., pregnancy, lactation, thyroid disease)\n* Current medical or psychiatric instability (i.e., hospitalization required in the past three months)\n* Lifetime history of psychosis or bipolar disorder\n* History of neurological disorder or injury (i.e., stoke, head injury with \\>10 minutes loss of consciousness)\n* Current substance use disorder\n* BMI less than 19 kg\u002Fm\\^2\n* Acute suicidality requiring hospitalization\n* fMRI exclusions as specifiedd by the Center for Magnetic Resonance Research\n* Food allergy that cannot be accommodated through substitutions to the laboratory test snack",{"count":369,"type":23},100,"The purpose of this investigation is to identify the potentially crucial role of anticipatory reward mechanisms maintaining bulimic behavior (i.e., binge eating and purging) in bulimia nervosa (BN). The research will investigate neural and psychological anticipatory processes in BN, both in the scanner and the natural environment.",[31],"2026-01-05",{"date":374,"type":46},"2026-01-08",{"date":376,"type":46},"2022-04-01",{"date":378,"type":23},"2026-11-30",{"name":380,"class":52},"University of Minnesota",{"id":382,"slug":383,"hasResults":12,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":387,"eligibilityCriteria":388,"healthyVolunteers":12,"sex":18,"minAge":389,"maxAge":4,"enrollmentInfo":390,"targetDuration":4,"studyType":24,"phases":392,"briefSummary":393,"conditions":394,"keywords":396,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":53},"100598781","training-app-for-inhibitory-control-towards-food-100598781","NCT07075952","Training App for Inhibitory Control Towards Food","Testing FoodTraining (FoodT): A Mobile App to Train Inhibitory Control Towards Food and Augment Standard Treatment for People With Eating and Weight Disorders","FoodT-RCT","Inclusion Criteria:\n\n* BMI in the obesity range (\\>30) or a clinician-formulated diagnosis of binge eating disorder or bulimia nervosa;\n* knowledge of Italian or English;\n* access to a mobile device (e.g. smartphone, tablet).\n\nExclusion Criteria:\n\n* visual impairment not corrected by glasses\n* a diagnosis of psychosis;\n* intellectual disability.","16 Years",{"count":391,"type":23},113,[26],"The aim of this project is to test the feasibility, acceptability and clinical impact of a mobile app-based intervention (FoodTraining) to strengthen food-related inhibitory control over 4 weeks, in a sample of people with eating or weight disorders (i.e. obesity, binge-eating disorder (BED), or bulimia nervosa (BN)) receiving standard outpatient treatment (i.e., treatment as usual (TAU) encompassing guided self-help or psychotherapy, pharmacological therapy or diet). The training will be offered in addition to TAU (experimental group) and compared to TAU alone (control group).\n\nParticipants will complete questionnaires to measure eating behaviour, eating disorder psychopathology, symptoms of anxiety, depression and stress, social functioning and quality of life at baseline, 4 and 8 weeks. They will also complete momentary assessments using a mobile application (FoodTracker) to report on food intake along with related thoughts, emotions, and behaviours and will wear small, non-invasive sensors to track real-time fluctuations in glucose levels for 15 days.\n\nParticipants will also perform a food-related go-no go task and a food-related temporal discounting task at baseline, 4 and 8 weeks.\n\nFinally, this study will pilot the use of a semi-structured interview to characterise the history of weight, the appetite system, eating-related habits in the family and learning of eating behaviours and attitudes in people with eating or weight disorders.",[395,31,227],"Obesity &Amp; Overweight",[397,398,399,31,227,400],"App","Training","Inhibitory control","Obesity","2025-12-22",{"date":403,"type":46},"2025-12-30",{"date":405,"type":46},"2025-10-01",{"date":407,"type":23},"2027-03",{"name":409,"class":52},"University of Padova",{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":416,"eligibilityCriteria":417,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":194,"enrollmentInfo":418,"targetDuration":4,"studyType":24,"phases":420,"briefSummary":421,"conditions":422,"keywords":423,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":53},"100615658","sleep-and-activity-for-eating-disorders-100615658","NCT07295470","Sleep and Activity For Eating Disorders","Sleep and Activity For Eating Disorders (SAFE): a Cross-sectional and Prospective Study on the Sleep Parameters.","SAFE","Inclusion Criteria:\n\n* a) Age over 18 and under 65;\n* b) Diagnosis of anorexia nervosa, bulimia nervosa, or binge-eating disorder, as indicated by DSM-5-TR criteria;\n* c) Adherence to the rehabilitation program.\n\nExclusion Criteria:\n\n* a) Presence of severe bradycardia (BPM \\\u003C 35);\n* b) Severe malnutrition (BMI \\\u003C 10);\n* c) Presence of severe psychopathology other than the eating disorder (e.g., schizophrenia);\n* d) Need to modify psychotropic or sleep-inducing pharmacological therapy during the rehabilitation program.",{"count":419,"type":23},75,[26],"The SAFE (i.e., Sleep and Activity For Eating disorders) study aims to investigate the characteristics of sleep, daytime activity, and circadian rhythms in a sample of patients with eating disorders-specifically anorexia nervosa, bulimia nervosa, and binge-eating disorder-as well as the relationship between these variables and physiological parameters (i.e., body mass index, hormone levels, blood chemistry parameters) and psychological parameters (i.e., levels of depression and anxiety, body image, eating-disorder symptoms).",[29,30,31,32],[424,425,426],"Sleep","Circadian rhythms","Eating disorders","2025-12-16",{"date":429,"type":46},"2025-12-19",{"date":431,"type":23},"2026-02",{"date":433,"type":23},"2027-07",{"name":435,"class":52},"Istituto Auxologico Italiano",{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":440,"acronym":441,"eligibilityCriteria":442,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":443,"enrollmentInfo":444,"targetDuration":4,"studyType":157,"phases":4,"briefSummary":446,"conditions":447,"keywords":466,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":488,"locationsCount":212},"100609246","precision-subclassification-of-mental-health-in-diabetes-digital-twins-for-precision-mental-health-to-track-subgroups-100609246","NCT07212075","Precision Subclassification of Mental Health in Diabetes: Digital Twins for Precision Mental Health to Track Subgroups","TwinPeaks","Inclusion Criteria:\n\n* 18 to 80 years of age\n* Diagnosis of type 1 diabetes or type 2 diabetes or other specific type of diabetes\n* Diabetes duration ≥ 1 year\n* Sufficient German language skills\n* Informed consent\n\nExclusion Criteria:\n\n* Inability to consent\n* Significant cognitive impairment (e.g. dementia)\n* Severe disorder or condition impacting the person's ability to participate in the study or likely to confound results (e.g. treated cancer, heart disease ≥ NYHA III, schizophrenia\u002Fpsychotic disorder)\n* Terminal illness\n* Being bedridden","80 Years",{"count":445,"type":23},1809,"Mental conditions and disorders (e.g. distress, depressive, anxiety, and eating disorders) are more prevalent in people with diabetes (PWD) and associated with reduced quality of life and impaired glycaemic outcomes. Evidence supports a complex network between psychosocial factors and glycaemic control that can be highly variable between persons. It is assumed that subgroups exist that show different trajectories of glycaemia and mental health.\n\nBelonging to a particular subgroup may be linked with a higher risk of developing mental health problems compared to others. This suggests that it is possible to treat individuals in different subgroups in a manner that optimizes their treatment and can improve health outcomes. Accurate characterisation can inform more individualized care. This calls for a more personalised approach considering the idiosyncrasies of different subgroups.\n\nOver 3 years, the investigators have established the basis of a precision mental health approach for diabetes using n-of-1 analyses. By utilizing combined ecological momentary assessment (EMA: repeated daily sampling of psychosocial factors in everyday life) and continuous glucose monitoring (CGM), intensive longitudinal data per person could be collected. This enables the analysis of individual associations between glycaemic parameters and psychosocial variables and identification of individual sources of diabetes distress in each person.\n\nThe objective of the present study is to use of the n-of-1 approach to identify subgroups of PWD who share common characteristics in the associations between glucose and psychosocial variables. The identified subgroups shall be used to develop a digital twin for precision mental health in diabetes. The digital twin serves as representation of a real person, allowing to make simulations and predictions of the course of mental health and glycaemia. These predictions can inform diabetes care and lead to more precise, personalised treatment decisions.\n\nTo achieve this, a longitudinal panel including over 1,400 PWD who continuously complete EMA and questionnaire surveys and measure glucose levels using CGM was developed. Over 1000 clinical interviews to diagnose mental disorders have been conducted to identify major mental health conditions and map mental outcomes. To identify subgroups and develop the digital twin, the sampling will be expanded aiming at a total of 1,809 PWD. Incidence and remission of mental disorders will be determined via repeated interviews.\n\nThe complex networks between clinical, metabolic, and psychosocial data will be analysed using machine learning, leading to new insights with the potential to shape future guidelines. These results will be used by the digital twin to predict courses of glycaemic control and mental health, translating the individual evidence into direct treatment suggestions.",[448,449,450,451,452,453,454,455,456,457,458,459,460,30,31,461,462,463,464,465],"Diabetes (DM)","Diabete Mellitus","Diabete Type 1","Diabete Type 2","Diabetes Distress","Diabetes Complications","Depression - Major Depressive Disorder","Depression Anxiety Disorder","Depression Bipolar","Depression Disorders","Anxiety Disorder (Panic Disorder or GAD)","Anxiety Disorder NOS","Eating Disorder Binge","Eating Disorder Not Otherwise Specified","Depressed Mood","Anxiety Symptoms","Disordered Eating Behaviors","Fear of Hypoglycemia",[467,468,469,470,471,472,473,474,475,476,477,478,479,480,481,452,441],"Digital Twin","Precision Medicine","Precision Mental Health","Subclassification","Trajectories","Subtypes","Person-reported Outcomes (PRO)","Ecological Momentary Assessment (EMA)","Continuous Glucose Monitoring (CGM)","People with Diabetes (PWD)","Diabetes Mellitus","HbA1c","Depression","Anxiety","Eating disorder","2025-11-27",{"date":484,"type":46},"2025-12-04",{"date":486,"type":46},"2025-01-01",{"date":255,"type":23},{"name":489,"class":52},"Forschungsinstitut der Diabetes Akademie Mergentheim",{"id":491,"slug":492,"hasResults":12,"nctId":493,"briefTitle":494,"officialTitle":495,"acronym":496,"eligibilityCriteria":497,"healthyVolunteers":12,"sex":18,"minAge":498,"maxAge":499,"enrollmentInfo":500,"targetDuration":4,"studyType":24,"phases":501,"briefSummary":503,"conditions":504,"keywords":506,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":53},"100478383","early-phase-1-naltrexone-neuroimaging-in-teens-with-eating-disorders-100478383","NCT05509257","Naltrexone Neuroimaging in Teens With Eating Disorders","Development of a Pharmacodynamic Biomarker of Opioid Antagonism in Adolescents With Eating Disorders","NN-RCT","Inclusion Criteria:\n\n* Adolescents and young adults aged 13-21 years\n* Eating disorder diagnosis characterized by binge eating and\u002For purging (eg, Anorexia Nervosa-Binge\u002FPurge, Bulimia Nervosa, Binge Eating Disorder, Other Specified Feeding\u002FEating Disorder) using Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V) criteria.\n* Stable medication regimen (no dose or drug changes in the past 4 weeks)\n* Participant and parent\u002Flegal guardian (if under 18 years) are willing and able to provide informed permission\u002Fassent\u002Fconsent for the study\n\nExclusion Criteria:\n\n* Pregnant (via UCG)\n* Prior hypersensitivity reaction to naltrexone (e.g., anaphylaxis)\n* Non-removable metal in the body that is magnetic resonance imaging incompatible\n* Current naltrexone use\n* Self-reported opioid use in the past 7 days\n* A language barrier (e.g., non-English speaking) for the participant that precludes communication and\u002For ability to complete all study-related requirements.","13 Years","21 Years",{"count":121,"type":23},[502],"EARLY_PHASE1","Using a randomized, placebo-controlled, crossover study, this study will evaluate functional magnetic resonance imaging (fMRI) as a pharmacodynamic biomarker of opioid antagonism in adolescents with eating disorders. The hypothesis is that fMRI will be able to detect acute reward pathway modulation by naltrexone (an opioid antagonist) in pre-defined regions of interest (anterior cingulate cortex, nucleus accumbens, dorsolateral prefrontal cortex).",[29,69,126,31,505],"Anorexia Nervosa, Atypical",[507,508,509,510,511,512],"Pediatric","Adolescent","Eating Disorder","Neuroimaging","Naltrexone","Pharmacodynamic Biomarker","2025-11-20",{"date":515,"type":46},"2025-11-25",{"date":517,"type":46},"2022-09-17",{"date":519,"type":23},"2027-06",{"name":521,"class":52},"Children's Mercy Hospital Kansas City",{"id":523,"slug":524,"hasResults":12,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":528,"eligibilityCriteria":529,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":530,"targetDuration":4,"studyType":24,"phases":532,"briefSummary":533,"conditions":534,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":539,"completionDateStruct":541,"leadSponsor":543,"locationsCount":53},"100462625","building-an-equitable-and-accessible-system-of-eating-disorder-care-for-va-dod-and-underrepresented-americans-100462625","NCT05304104","Building an Equitable and Accessible System of Eating Disorder Care for VA, DoD, and Underrepresented Americans","Building an Equitable and Accessible System of Eating Disorder Care for VA, DoD, and Underrepresented Americans With Eating Disorders (EASED Study)","EASED","Inclusion Criteria:\n\n* Aged 18 and older\n* Presence of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) Bulimia Nervosa (BN) or Binge Eating Disorder (BED)\n* Veteran Health Administration (VHA) user\n\nExclusion Criteria:\n\n* Active psychosis or high acute risk for suicide\n* Medical or psychiatric illness, or cognitive deficits, that interfere with providing consent, completing assessments, or engaging in treatment for eating disorders\n* Pregnancy or lactation\n* Patients with suspected Anorexia or Atypical Anorexia will be excluded and referred to other VA care services",{"count":531,"type":23},144,[26],"When untreated, eating disorders present with tremendous burdens to affected active duty Service members and Veterans and their families, and are very costly to the DoD and VA healthcare system. A comparative effectiveness study with state-of-the-art virtual treatment for BN and BED specifically adapted for testing with the Veteran population and other underrepresented eating disorder populations will lead to major improvements in clinical outcomes. The treatment will be integrated with VA's newest telehealth technology to profoundly enhance access to care anywhere, at any time. This trial of therapist-led and self-help CBT treatments, combined with our expert panel methods to inform VA Clinical Practice Guidelines for Eating Disorders and plans for dissemination, will accelerate the pace for the transition of results both for large-scale deployment in the VA system and for real-world impact among diverse and underrepresented eating disorder populations.",[227,31,535,536],"Veterans Health","Cognitive Behavioral Therapy","2025-11-19",{"date":515,"type":46},{"date":540,"type":46},"2022-04-22",{"date":542,"type":23},"2025-12",{"name":544,"class":545},"VA Connecticut Healthcare System","FED",{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":550,"acronym":551,"eligibilityCriteria":552,"healthyVolunteers":12,"sex":18,"minAge":220,"maxAge":4,"enrollmentInfo":553,"targetDuration":4,"studyType":157,"phases":4,"briefSummary":555,"conditions":556,"keywords":557,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":567,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":572,"locationsCount":53},"100601555","development-of-gastrointestinal-symptoms-in-patients-with-anorexia-nervosa-and-bulimia-nervosa-during-weight-rehabilitation-over-time-depending-on-the-nutritional-strategy-100601555","NCT07112014","Development of Gastrointestinal Symptoms in Patients With Anorexia Nervosa and Bulimia Nervosa During Weight Rehabilitation Over Time, Depending on the Nutritional Strategy","GastroRehab","Inclusion Criteria:\n\n* patients diagnosed with anorexia nervosa (all subtypes)\n* patients diagnosed bulimia nervosa\n\nExclusion Criteria:\n\n* patients that are medically unable to fill out a short questionnaire on a weekly base.",{"count":554,"type":23},185,"This prospective observational study investigates the development of gastrointestinal (GI) symptoms in patients with anorexia nervosa (AN) and bulimia nervosa (BN) during multi-week inpatient weight rehabilitation. The study explores how the predominant nutritional strategy-flexitarian, vegetarian, or vegan-relates to changes in GI symptoms over the course of treatment. In addition to diet, the study examines how weight gain and other clinical, psychological, and demographic factors influence the trajectory of GI symptoms. Patients complete weekly questionnaires assessing GI symptoms as part of routine care at the Eating Disorder Center of the Klinik Lüneburger Heide, Germany. Further data are drawn from standard clinical assessments, including body weight, body composition, and psychometric instruments. The primary outcome is the change in GI symptom severity (measured via the GSRS score) from admission to discharge, analyzed in relation to dietary pattern and weight development. Secondary analyses will explore symptom progression over time, group differences between AN and BN, and predictors of GI symptom improvement, including dietary intake, baseline psychological status, symptom change, weight trajectory, and treatment duration. The outcomes will be analyzed separately for AN and BN. The study aims to recruit approximately 150 patients with AN and 35-40 with BN. Inclusion requires a diagnosis of AN (any subtype) or BN, age over 12 years, clinical stability, and the ability to provide informed consent. The findings aim to inform evidence-based dietary recommendations for individuals with eating disorders who experience significant GI symptoms during nutritional rehabilitation.",[30,31],[558,559,560,561,562,563,564,565],"gastrointestinal symptoms","gastrointestinal health","dietary regime","psychological health","vegetarian diet","vegan diet","balanced diet","energy intake","2025-09-17",{"date":568,"type":46},"2025-09-23",{"date":570,"type":46},"2025-09-09",{"date":255,"type":23},{"name":573,"class":52},"University Hospital Tuebingen",{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":579,"acronym":4,"eligibilityCriteria":580,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":243,"enrollmentInfo":581,"targetDuration":4,"studyType":24,"phases":582,"briefSummary":583,"conditions":584,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":587,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":592,"locationsCount":53},"100516150","therapeutic-ketogenic-diet-in-anorexia-nervosa-100516150","NCT06000774","Therapeutic Ketogenic Diet in Anorexia Nervosa","Ketogenic Diet in Eating Disorders to Target Metabolism and Normalize Persistent Eating Disorder Psychopathology","Weight-Recovered AN Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Persons, aged 18 to 45 years\n4. History of anorexia nervosa according to DSM-5 criteria\n5. Weight recovered at the time of study inclusion (body mass index \\> 17.5 kg\u002Fm2)\n6. Greater or equal to 2 standard deviations scores of eating disorder-relevant behaviors on the Eating Disorder Inventory-3 and Eating Disorder Examination Questionnaire\n7. The following types of psychiatric medications are allowed: antidepressant, anxiolytic, atypical antipsychotic, mood stabilizers\n8. English is primary spoken language\n\nWeight-Recovered AN Exclusion Criteria:\n\n1. Pregnancy or lactation\n2. Electrolyte, blood count, kidney function or liver function abnormalities\n3. Psychosis\n4. Neurocognitive disorders including dementias or traumatic brain injury that is symptomatic\n5. Current alcohol use disorder (AUD) or substance use disorder (SUD) according to DSM-5 criteria\n6. Uncontrolled hypertension\n7. Hepatic impairment (Class-Pugh b or c)\n8. Diabetes mellitus\n9. Family history of porphyria\n10. History of recent heart attack, vascular disease, or any other current acute medical conditions as determined by the principal investigator\n11. Inability or unwillingness to adhere to the TKD diet for the duration of the study\n12. Blind or illiterate individuals\n\nUnderweight AN Sub-Study Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Persons, aged 18 to 45 years\n4. Anorexia nervosa according to DSM-5 criteria\n5. Current Body Mass Index (BMI) at the time of study inclusion of 16.0 to 17.49\n6. An elevated EDE-Q global score of 2.09 or greater\n7. The following types of psychiatric medications are allowed: antidepressant, anxiolytic, atypical antipsychotic, mood stabilizers\n8. English is primary spoken language\n\nUnderweight AN Sub-Study Exclusion Criteria:\n\n1. Pregnancy or lactation\n2. Electrolyte, blood count, kidney function or liver function abnormalities\n3. Psychosis\n4. Neurocognitive disorders including dementias or traumatic brain injury that is symptomatic\n5. Current alcohol use disorder (AUD) or substance use disorder (SUD) according to DSM-5 criteria\n6. Uncontrolled hypertension\n7. Hepatic impairment (Class-Pugh b or c)\n8. Diabetes mellitus\n9. Family history of porphyria\n10. History of recent heart attack, vascular disease, or any other current acute medical conditions as determined by the principal investigator\n11. Inability or unwillingness to adhere to the TKD diet for the duration of the study\n12. Blind or illiterate individuals\n\nBulimia Nervosa Pilot Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Persons, aged 18 to 45 years\n4. History of bulimia nervosa according to DSM-5 criteria\n5. An elevated EDE-Q global score of 2.09 or greater\n6. The following types of psychiatric medications are allowed: antidepressant, anxiolytic, atypical antipsychotic, mood stabilizers\n7. English is primary spoken language\n\nBulimia Nervosa Pilot Exclusion Criteria:\n\n1. Pregnancy or lactation\n2. Electrolyte, blood count, kidney function or liver function abnormalities\n3. Psychosis\n4. Neurocognitive disorders including dementias or traumatic brain injury that is symptomatic\n5. Current alcohol use disorder (AUD) or substance use disorder (SUD) according to DSM-5 criteria\n6. Uncontrolled hypertension\n7. Hepatic impairment (Class-Pugh b or c)\n8. Diabetes mellitus\n9. Family history of porphyria\n10. History of recent heart attack, vascular disease, or any other current acute medical conditions as determined by the principal investigator\n11. Inability or unwillingness to adhere to the TKD diet for the duration of the study\n12. Blind or illiterate individuals",{"count":223,"type":23},[26],"This study will investigate the effects of therapeutic ketogenic diet (TKD) on eating behavior including drive to restrict, body dissatisfaction, mood and anxiety in individuals with anorexia nervosa who have been weight normalized (body mass index of 17.5 or greater) but continue to struggle with eating disorder behaviors including a high drive for thinness and body dissatisfaction.\n\nThe Underweight Anorexia Nervosa (AN) Sub-Study will investigate the effects of TKD on eating behavior including drive to restrict, body dissatisfaction, mood and anxiety in individuals with anorexia nervosa who are currently underweight (body mass index between 16.0 and 17.49) and continue to struggle with eating disorder behaviors including a high drive for thinness and body dissatisfaction.\n\nThe Bulimia Nervosa Pilot will will investigate the effects of TKD on eating behavior including drive to binge and purge, body dissatisfaction, mood and anxiety in individuals with bulimia nervosa.",[585,31,30],"Anorexia Nervosa in Remission","2025-08-28",{"date":588,"type":46},"2025-09-05",{"date":590,"type":46},"2023-10-03",{"date":233,"type":23},{"name":168,"class":52},{"id":594,"slug":595,"hasResults":12,"nctId":596,"briefTitle":597,"officialTitle":598,"acronym":599,"eligibilityCriteria":600,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":194,"enrollmentInfo":601,"targetDuration":4,"studyType":24,"phases":603,"briefSummary":604,"conditions":605,"keywords":607,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":610,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":616,"locationsCount":53},"100565422","technological-balance-rehabilitation-in-feed-and-eating-disorders-100565422","NCT06641973","Technological Balance Rehabilitation in Feed and Eating Disorders","Technological Balance and Gait Rehabilitation in Patients With Feed and Eating Disorders: Effects on Functional, Motor, and Cognitive Outcomes","ROAR-FED","Inclusion Criteria:\n\n* Age between 18 and 65 years;\n* Diagnosis of AN, BN, DAI according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders-5 Edition, DSM-5)\n* Ability to walk independently or with little assistance;\n* Ability to understand and sign informed consent.\n\nExclusion Criteria:\n\n* Current or past cognitive disorders (mental retardation) with Mini Mental State Evaluation (MMSE) values ≤ 26 ;\n* Severe clinical conditions (head trauma, severe neurological and cardiac diseases and vascular disorders, oncological diseases);\n* Substance use disorders;\n* Unstabilized major psychiatric disorders (e.g., manic episode, acute psychotic episode, etc.);\n* Taking medications that alter cardiac activity;\n* Orthopedic or postural problems;\n* Presence of plantar ulcers;\n* Partial or total amputation of foot segments;\n* Inability to provide informed consent.",{"count":602,"type":23},72,[26],"Postural control depends on the central integration of vestibular, visual, and somatosensory inputs and the integrity of the neural efferent motor pathway, which continuously provides postural adjustments to environmental and body position changes. It is considered a complex skill and involves the integration of movement strategies necessary for maintaining balance. Decreased postural control can induce instabilities that affect the performance of daily activities and increase the risk of falls. Decreased postural control can be linked to fluctuations in body weight: significant weight gain or loss, in fact, can induce musculoskeletal adaptations , which contribute to postural and motor alterations . In Italy, approximately 3 million people are affected by Feed and Eating Disorders (FED), which include, among others, anorexia nervosa (AN), bulimia nervosa (BN) and uncontrolled eating disorder (UED). There are works in the literature highlighting that both anorexic and obese patients present with impaired postural control and, consequently, reduced balance.",[606,30,31],"Feeding Disorders",[608,606],"Rehabilitation","2025-07-11",{"date":611,"type":46},"2025-07-14",{"date":613,"type":23},"2025-09",{"date":615,"type":23},"2027-09",{"name":617,"class":52},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":619,"slug":620,"hasResults":12,"nctId":621,"briefTitle":622,"officialTitle":622,"acronym":623,"eligibilityCriteria":624,"healthyVolunteers":153,"sex":18,"minAge":220,"maxAge":625,"enrollmentInfo":626,"targetDuration":4,"studyType":157,"phases":4,"briefSummary":628,"conditions":629,"keywords":631,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":637,"lastUpdatePostDateStruct":638,"startDateStruct":640,"completionDateStruct":642,"leadSponsor":644,"locationsCount":646},"100561803","eating-disorders-genetics-initiative-2-100561803","NCT06594913","Eating Disorders Genetics Initiative 2","EDGI2","Inclusion Criteria:\n\n* A lifetime history of anorexia nervosa, bulimia nervosa, binge-eating disorder, avoidant restrictive food intake disorders or no history of any disordered eating behavior, based on DSM-5 criteria algorithms\n* Age 12-99 years, depending on country. (US enrollment age is 18-99)\n\nExclusion Criteria:\n\n* History of subthreshold disordered eating behaviors.","99 Years",{"count":627,"type":23},20000,"The overarching intention of the Eating Disorder Genetics Initiative 2 (EDGI2) is to increase sample size, diversity, and eating disorder phenotypes. The investigators are enrolling 20,000 new participants with anorexia nervosa (AN), bulimia nervosa (BN), binge-eating disorder (BED), avoidant\u002Frestrictive food intake disorder (ARFID), and controls in the US, Mexico, Australia, New Zealand, Sweden, and Denmark. A primary study goal is to enroll at least 30% of participants from underrepresented groups. Participants are asked to complete a series of questionnaires and submit a saliva sample for genotyping. The goal is to better understand eating disorders and how they relate to each other so that better treatments can be developed.",[30,31,227,630],"Avoidant Restrictive Food Intake Disorder",[632,633,634,635,636],"severe and enduring eating disorder","genetics","mental health","disordered eating","environmental factors","2025-05-30",{"date":639,"type":46},"2025-05-31",{"date":641,"type":46},"2024-10-28",{"date":643,"type":23},"2027-08-01",{"name":645,"class":52},"University of North Carolina, Chapel Hill",5,{"id":648,"slug":649,"hasResults":12,"nctId":650,"briefTitle":651,"officialTitle":652,"acronym":653,"eligibilityCriteria":654,"healthyVolunteers":153,"sex":18,"minAge":655,"maxAge":656,"enrollmentInfo":657,"targetDuration":4,"studyType":24,"phases":659,"briefSummary":660,"conditions":661,"keywords":662,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":667,"lastUpdatePostDateStruct":668,"startDateStruct":670,"completionDateStruct":672,"leadSponsor":674,"locationsCount":53},"100577566","ai-and-vr-devices-for-eating-behavior-rehabilitation-100577566","NCT06799962","AI and VR Devices for Eating Behavior Rehabilitation","Assistance and Rehabilitation of Eating Behavior Through Devices Based on Artificial Intelligence and Virtual Reality","ARCADIA-VR","Inclusion Criteria:\n\n* Clinical diagnosis of Anorexia Nervosa or Bulimia Nervosa according to DSM-5-TR (APA, 2013) and ICD-11, confirmed by a public hospital setting\n* Body Mass Index (BMI) between 16 and 32\n* Disorder present for at least 6 months\n* No other concurrent psychotherapeutic interventions during the study\n* All participants with a previous diagnosis will be re-evaluated and confirmed through assessment and consent by expert professionals in the research team (i.e., a neuropsychiatrist and a clinical psychologist)","15 Years","40 Years",{"count":658,"type":23},80,[26],"Eating disorders (ED) affect the relationship with food and body image. Virtual reality (VR), combined with artificial intelligence (AI), offers new clinical solutions, overcoming traditional cognitive behavioral therapy (CBT). The ARCADIA VR project aims to develop devices to treat ED through personalized VR systems (e.g. Enhanced Body-Swap for anorexia, Emotional Rescripting for bulimia) and AI predictive algorithms to monitor severity, risk and efficacy of treatments. These approaches promise better and faster results, improving diagnosis and treatment.",[29,30,31],[29,30,31,663,664,665,666,536],"Virtual Reality","Artificial Intelligence","Body Perception","Emotional Regulation","2025-04-29",{"date":669,"type":46},"2025-04-30",{"date":671,"type":46},"2025-01-30",{"date":673,"type":23},"2026-01-31",{"name":675,"class":52},"Istituto per la Ricerca e l'Innovazione Biomedica",{"id":677,"slug":678,"hasResults":12,"nctId":679,"briefTitle":680,"officialTitle":681,"acronym":4,"eligibilityCriteria":682,"healthyVolunteers":12,"sex":87,"minAge":220,"maxAge":656,"enrollmentInfo":683,"targetDuration":4,"studyType":157,"phases":4,"briefSummary":685,"conditions":686,"keywords":687,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":690,"lastUpdatePostDateStruct":691,"startDateStruct":693,"completionDateStruct":695,"leadSponsor":697,"locationsCount":699},"100583286","functional-mri-during-resting-state-in-patients-with-eating-disorders-100583286","NCT06874348","Functional MRI During Resting State in Patients with Eating Disorders","Functional MRI During Resting State in Patients with Eating Disorders: a Longitudinal Prospective Study on Neuropsychopathological Correlates","Inclusion Criteria:\n\n* Female sex\n* Age between 12 and 40 years old\n* Current diagnosis of Anorexia Nervosa or Bulimia Nervosa according to DSM-5-TR.\n\nExclusion Criteria:\n\n* Previous or current diagnosis of schizophrenia or bipolar disorder,\n* Acute psychosis\n* Substance abuse\n* Severe medical comorbidities (hypercapnia, severe hypertension, cardiac arrhythmia, organ failure)\n* incapacity to grant written or verbal consent",{"count":684,"type":23},50,"The goal of this observational study is to learn if clinical and neurophysiological characteristics dynamics may follow similar trends in a longitudinal characterization of patients with a diagnosis of an eating disorder.\n\nThe primary hypothesis is that the reversal of Functional Magnetic Resonance Imaging (fMRI) baseline alternations is positively associated with symptomatic amelioration.\n\nThe secondary hypothesis is that the degree of (f)MRI baseline alternations is positively associated with symptoms.\n\nParticipants will be asked to complete psychometric questionnaires, perform a fMRI and be recalled at 12 months for a follow-up.",[30,31],[688,689],"resting state fMRI","longitudinal evaluation","2025-03-11",{"date":692,"type":46},"2025-03-13",{"date":694,"type":46},"2024-10-24",{"date":696,"type":23},"2026-10",{"name":698,"class":52},"Meyer Children's Hospital IRCCS",2,{"id":701,"slug":702,"hasResults":12,"nctId":703,"briefTitle":704,"officialTitle":704,"acronym":705,"eligibilityCriteria":706,"healthyVolunteers":12,"sex":18,"minAge":193,"maxAge":4,"enrollmentInfo":707,"targetDuration":709,"studyType":157,"phases":4,"briefSummary":710,"conditions":711,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":712,"lastUpdatePostDateStruct":713,"startDateStruct":715,"completionDateStruct":717,"leadSponsor":719,"locationsCount":53},"100573901","a-longitudinal-study-of-severe-and-enduring-eating-disorders-100573901","NCT06752304","A Longitudinal Study of Severe and Enduring Eating Disorders","Long-SEED","Inclusion criteria:\n\n* found to meet the criteria for an eating disorder\n* being in need of treatment\n* having provided written informed consent (for minors, this includes consent from all caregivers and the minors themselves).\n\nExclusion criteria:\n\n* Eating disorders symptoms in need of emergency care\n* High risk for suicide\n* An inability to respond to the questionnaires due to e.g., lack of knowledge in Swedish.",{"count":708,"type":23},800,"20 Years","The goal of this observational longitudinal study is to investigate characteristics and factors associated with the development of Severe and Enduring Eating Disorders (SEED). In this project, the researchers will follow two prospective cohorts of patients with eating disorders (ED), one adolescent (ages 14-17) and one adult (ages 18+), in terms of change in and impact of clinical, psychological, and biological risk factors.\n\nData will be collected at baseline, after treatment, two years after baseline, and thereafter five, 10 and 20 years after baseline. Participants will be asked to undergo a physical examination, leave blood samples, be interviewed, and fill in questionnaires. If the participants are minors, their care takers will also fill in the questionnaires.\n\nThe study aims to explore how clinical, psychological, and biological risk factors-including comorbidity, personality characteristics, difficulties with emotion regulation (ER), cognitive inflexibility, loneliness, severe ED symptoms, and inflammatory activation-contribute to a chronic course of the disorder.",[29,30,31,32,33],"2024-12-28",{"date":714,"type":46},"2024-12-31",{"date":716,"type":46},"2024-09-01",{"date":718,"type":23},"2048-12",{"name":720,"class":52},"Uppsala University Hospital",{"id":722,"slug":723,"hasResults":12,"nctId":724,"briefTitle":725,"officialTitle":725,"acronym":726,"eligibilityCriteria":727,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":728,"targetDuration":729,"studyType":157,"phases":4,"briefSummary":730,"conditions":731,"keywords":733,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":736,"lastUpdatePostDateStruct":737,"startDateStruct":739,"completionDateStruct":741,"leadSponsor":743,"locationsCount":53},"100561653","unfolding-severe-and-enduring-eating-disorders-u-seed-100561653","NCT06592963","Unfolding Severe and Enduring Eating Disorders (U-SEED)","U-SEED","For aim 1 (register based cohort):\n\nIncl. criteria:\n\nAttended care for eating disorders at Uppsala University Hospital between 2005 and 2007 and accepted to be included in a local quality register.\n\nExcl. criteria: None\n\nFor aim 2 (ongoing SEED sample and register based cohort)\n\nIncl. criteria:\n\n* For ongoing SEED sample: Minimum age of 18, impairing eating disorder symptoms for at least seven years, and having at least one evidence-based treatment without remission or resulting in relapse.\n* For register based cohort, see above.\n\nExcl. criteria:\n\n* For ongoing SEED sample: Eating disorders symptoms in need of emergency care, high risk for suicide, and an inability to respond to the questionnaires due to lack of knowledge in Swedish.\n\nFor aim 3 and 4 (the ongoing SEED sample). See above.",{"count":684,"type":23},"2 Weeks","The main aim of this study is to identify biological and psychological characteristics as risk factors in individuals with severe and enduring eating disorders (SEED).\n\nSpecifically, the investigators aim to:\n\n1. in a cohort of well-diagnosed eating disorder patients from 2005 followed up in National health registers, explore risk factors at baseline (recorded 2005-2007) for development of later SEED (the registry based cohort).\n2. replicate the findings in a new sample of 50 adults with ongoing SEED. Participants will be assessed diagnostically and physically, and asked to fill out questionnaires and leave blood samples (the ongoing SEED sample compared with the register based cohort).\n3. in a sample of 50 adults with SEED, explore demographic, biological, clinical, and psychological factors and examine the relation between these factors and symptom severity and functional impairment (the ongoing SEED sample).\n4. explore participants perspectives on their symptoms and received care (the ongoing SEED sample).",[29,30,31,227,732],"Personality Disorders",[734,735],"Registers","Severe and Enduring Eating Disorders","2024-09-09",{"date":738,"type":46},"2024-09-19",{"date":740,"type":46},"2024-06-01",{"date":742,"type":23},"2026-04",{"name":720,"class":52}]